Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients

Antiviral drugs have shown little impact in patient infected with acute respiratory coronavirus 2 (SARS-CoV-2). Especially for immunocompromised persons positive for SARS-CoV-2, novel treatments are warranted. Recently, the U.S. FDA has granted an emergency use authorization (EUA) to two monoclonal...

Full description

Saved in:
Bibliographic Details
Published in:Transplant international 2022-03, Vol.35, p.10109-10109
Main Authors: Bachmann, Friederike, Budde, Klemens, Suttorp, Norbert, Lingscheid, Tilman, Stegemann, Miriam Songa, Osmanodja, Bilgin, Schrezenmeier, Eva, Duettmann, Wiebke, Weber, Ulrike, Naik, Marcel, Lehner, Lukas Johannes, Kahl, Andreas, Duerr, Michael, Eckardt, Kai-Uwe, Waiser, Johannes, Choi, Mira, Halleck, Fabian
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing - therapeutic use
Antineoplastic Agents, Immunological
COVID-19
Health Archive
Humans
Kidney - physiology
Pancreas
SARS-CoV-2
Transplant Recipients
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antiviral drugs have shown little impact in patient infected with acute respiratory coronavirus 2 (SARS-CoV-2). Especially for immunocompromised persons positive for SARS-CoV-2, novel treatments are warranted. Recently, the U.S. FDA has granted an emergency use authorization (EUA) to two monoclonal antibodies (mAb) targeting the viral spike protein: bamlanivimab and casivirimab and imdevimab. As per the EUA, all SARS-CoV-2 positive organ transplant recipients can receive mAb treatment. We queried our center's transplant registry to identify SARS-CoV-2 infected recipients treated with single doses of either Bamlanivimab or casivirimab/imdevimab up to May 31, 2021. We analyzed clinical outcomes, renal function and virus-specific antibodies. The co-primary endpoints were hospitalization due to COVID-19 and SARS-CoV-2 RT-PCR negativity. Thirteen patients at a median interval of 55 (IQR, 26-110) months from transplant were treated: 8 with bamlanivimab and 5 with casivirimab/imdevimab. In all, 4/13 (31%) patients were hospitalized at some time, while 11/13 (85%) achieved PCR negativity. 2/4 hospitalized patients received mAb as rescue treatment. Overall mortality was 23%, with one death attributable to transplant-associated lymphoma. All six patients infected with the B 1.1.7 variant were alive at last contact. : mAb treatment appears effective when administered early to SARS-CoV-2-infected transplant recipients.
ISSN:1432-2277
0934-0874
1432-2277
DOI:10.3389/ti.2022.10109